Search clinical trials for: GSK3326595

Total 3 results

Ottawa Hospital Research Institute
GlaxoSmithKline; Hamilton Health Sciences Corporation; London Regional Cancer... and other collaborators

Completed

A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer (OTT-19-06)

Breast Cancer

Canada
GlaxoSmithKline

Terminated

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Neoplasms

United States, Canada
GlaxoSmithKline

Completed

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (Meteor 1)

Neoplasms

United States, Netherlands, Canada, France

3

Subscribe